je.st
news
Tag: infection
Officials investigate infection linked to 18 deaths in Wisconsin
2016-03-04 17:10:43| Biotech - Topix.net
A team of federal, state and local investigators are looking for the source of a bacterial bloodstream infection linked to 18 deaths in Wisconsin. The Centers for Disease Control and Prevention has sent a team of investigators to Wisconsin to find out how the bacteria, Elizabethkingia, has infected 44 people.
Tags: linked
officials
wisconsin
investigate
Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
2016-01-29 00:59:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. ZEPATIER Achieves High Cure Rates (SVR12) in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZEPATIER (elbasvir and grazoprevir) for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection, with or without ribavirin (RBV), following priority review by the FDA. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
following
review
treatment
Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence
2016-01-27 14:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. FDA Grants Priority Review with Target Action Date of July 23, 2016 Marketing Authorization Application Also Filed with the European Medicines Agency KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence. The FDA granted Priority Review for bezlotoxumab, with a Prescription Drug User Fee Act (PDUFA) action date of July 23, 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
license
acceptance
prevention
Baby born in Hawaii with brain damage confirmed to have Zika infection
2016-01-17 07:29:14| Biotech - Topix.net
REUTERS: A baby born with brain damage at a hospital in Oahu, Hawaii, was infected by the Zika virus, U.S. health officials confirmed on Saturday, apparently the first case of the mosquito-borne virus in a birth on U.S. soil. The mother became ill with the Zika virus while living in Brazil in May 2015 and the baby was likely infected in the womb, Hawaiian state health officials and the U.S. Centers for Disease Control and Prevention said.
12.04.15 -- Promising New Antimicrobials Could Fight Drug-Resistant MRSA Infection, Study Finds
2015-12-03 00:58:04| drugdiscoveryonline Home Page
12/04/15 Drug Discovery Online Newsletter
Tags: study
fight
finds
infection
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »